The firm's next-generation pancreatic cancer test looks for five biomarkers that are indicative of early-stage disease.
Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...
From increasing fibre intake to staying hydrated and exercising regularly, know healthy diet and lifestyle tweaks to prevent ...
More than 700 oncologists, cancer researchers and advocates will converge on the Crescent City this week as part of the 2025 NeauxCancer Conference. The event got its start four years ago by the ...
The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of ...
The Texas Tribune on MSN13h
Gov. Greg Abbott showing no rush to replace late U.S. Rep. Sylvester TurnerRepublicans hold a tiny majority in the House, creating an incentive for Abbott to hold off on calling an election for Turner ...
StockNews.com upgraded shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a hold rating to a buy rating in a report ...
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further ...
Bayer obtains exclusive worldwide license for MTA-cooperative PRMT5 inhibitor for selective targeting of MTAP-deleted tumors ...
Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback